Hygetropin HGH 120IU

Hygetropin is produced by Zhongshan Hygene Biopharm, a Chinese manufacturer with longstanding presence in the international recombinant growth hormone market. Each kit contains 12 vials of 10IU lyophilized somatropin 191aa, totaling 120IU — a slightly larger supply than standard 100IU kits, positioned at $3.16 per IU. Hygetropin has built its reputation on manufacturing consistency and third-party batch verification: each kit includes anti-counterfeiting security codes verifiable against the manufacturer's database, and Novo Pharma independently tests incoming batches for amino acid sequence confirmation and purity assurance.

The pharmacological action is identical to all authentic 191aa somatropin: GHR-mediated JAK2-STAT5 signaling, hepatic IGF-1 production, direct adipocyte lipolysis via hormone-sensitive lipase, and enhanced protein synthesis across target tissues. Researchers using Hygetropin should expect the full spectrum of GH-mediated effects — improved body composition, accelerated recovery, enhanced sleep quality, collagen synthesis, and favorable metabolic partitioning. The 191aa sequence ensures bioequivalence with endogenous growth hormone and avoids the immunogenic concerns associated with 192aa generics.

The 120IU format offers a practical advantage over standard 100IU kits: at 3IU/day, it provides a full 40-day supply — approximately 20% more coverage than a 100IU kit at the same daily dose. This additional headroom reduces the likelihood of protocol interruption and bridges the gap between the 100IU entry point and larger bulk commitments. Hygetropin is well-suited for researchers who value manufacturer traceability and batch-level verification, or for those seeking to evaluate a different production source while maintaining the 191aa standard.

Reconstitution, storage, and administration follow the same protocols as all lyophilized somatropin: bacteriostatic water reconstitution without agitation, 2–8°C refrigeration, 20-day use window post-reconstitution, subcutaneous injection via insulin syringe. Unreconstituted vials should remain sealed and refrigerated until needed. Researchers running the full 120IU supply over extended timelines should reconstitute vials sequentially to maximize stability and potency.